Business
Helix Biopharma Corp. Expands Leadership Team with World-Class Oncology and Scientific Experts
(TheNewswire) March 6, 2025 – TheNewswire - Toronto, Ontario – Helix BioP...
About this update from Helix Biopharma Corp.
[{"type":"text","content":"Helix Biopharma Corp. Expands Leadership Team with World-Class Oncology and Scientific Experts\n\n\n (TheNewswire)\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n March 6, 2025 – TheNewswire -\n \n\n Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP”,\nOTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (\n \n\n “Helix”\n \n\n or the\n \n\n “Company”\n \n\n ), a clinical-stage oncology company shaping a near future\nwhere today’s hard-to-treat cancers are vincible, is pleased to\nannounce the addition of three esteemed experts in oncology and drug\ndevelopment to its executive team. The appointments underscore\nHelix’s commitment to assembling a world-class team to push the\nlimits of proven science and bring life-changing therapies to patients\nas soon as possible.\n \n\n\n\n\n\n i)\n \n\n\n Thomas Mehrling, MD, PhD – Chief Medical Officer\n(CMO)\n \n\n\n\n Dr. Thomas Mehrling (PhD in Pharmacology and MD, University of\nFrankfurt) brings 20 years of experience shaping the oncology\nlandscape, with previous roles at Takeda, Mundipharma International\nand Roche. His track record includes the successful introduction of\ngroundbreaking cancer drugs across Europe, with commercial successes\nnearing USD 1 billion in sales. As Chief Medical Officer, Dr. Mehrling\nwill lead Helix’s clinical development strategy, beginning with\nTumor Defence Breaker™ L-DOS47—a first-in-class, clinical-stage\nantibody-enzyme conjugate (AEC) to enhance the effectiveness of\ntoday’s immune-oncology therapies for the treatment of Non-Small\nCell Lung Cancer (NSCLC).\n \n\n\n\n\n\n\n\n ii)\n \n\n\n Jonathan Davis, PhD – Director of ADC Discovery\n \n\n\n\n\n A leading expert in therapeutic\nantibodies, Dr. Davis joins Helix as Director of Antibody-Drug\nConjugate (ADC) Discovery. With over 15 years of experience\nspearheading discovery and innovation strategies across diverse\ntherapeutic antibody formats—including monoclonal antibodies (mAbs),\nmultispecifics, and bi-specific ADCs (EMD Serono, Bristol-Myers\nSquibb, Invenra)—Dr. Davis will play a pivotal role in advancing\nHelix’s ADC portfolio targeting Carcinoembryonic Antigen-related\nCell Adhesion Molecule 6 (CECAM6). As of 2025, Helix is drawing on the\nlatest advance...